- Status:
- Red
- Decision Date:
- December 2019
Comments
NICE TA630: For treating neurotrophic tyrosine receptor kinase (NTRK) fusion positive solid tumours (Decision date - June 2020)
Red Drug Classifications
- 8. NHS England commissioned – to be used in line with NHSE commissioning intentions
search again
